Improved Adherence with Medicines Use Review Service in Slovenia: a Randomized Controlled Trial

Overview

Journal BMC Health Serv Res

Publisher Biomed Central

Specialty Health Services

Date 2021 Mar 23

PMID 33752647

Citations 2

Authors

Urska Nabergoj Makovec

Igor Locatelli

Mitja Kos

Affiliations

Soon will be listed here.

Abstract

Background: Based on several existing patient-oriented activities, Medicines Use Review (MUR) service was standardized and officially adopted in Slovenia in 2015. Service aims to provide adherence support and ensure safe and effective medicines use. Therefore, the aim of the study was to evaluate the benefits of MUR in Slovenia, primarily the impact on medication adherence.

Methods: A randomised controlled trial was performed in community pharmacies to compare MUR with standard care. Patients were randomised into either the test (patients received MUR by a certified MUR provider at visit 1), or control group. The study primary outcome was self-reported adherence to multiple medications, assessed by electronic ©Morisky Widget MMAS-8 Software at the first visit (V1) and after 12 weeks (V2). A sub-analysis of intentional and unintentional non-adherence was performed. MUR impact was defined as the relative difference in ©MMAS-8 score after 12 weeks between the test and control group. A multiple linear regression model was used to predict MUR impact based on baseline adherence (low versus medium and high). Several secondary outcomes (e.g. evaluation of drug-related problems (DRPs)) were also assessed.

Results: Data from 153 (V1) and 140 (V2) patients were analysed. Baseline adherence was low, moderate and high in 17.6, 48.4 and 34.0% patients, respectively. In the low adherence subpopulation, test group patients showed a 1.20 point (95% CI = 0.16-2.25) increase in total ©MMAS-8 score (p = 0.025) compared to control group patients. A 0.84 point (95% CI = 0.05-1.63) increase was due to intentional non-adherence (p = 0.038), and a 0.36 point (95% CI = - 0.23-0.95) was due to unintentional non-adherence (p = 0.226). Additionally, statistically significant decrease in the proportion of patients with manifested DRPs (p < 0.001) and concerns regarding chronic medicines use (p = 0.029) were revealed.

Conclusion: MUR service in Slovenia improves low medication adherence and is effective in addressing DRPs and concerns regarding chronic medicines use.

Trial Registration: ClinicalTrials.gov - NCT04417400 ; 4th June 2020; retrospectively registered.

Citing Articles

The Arabic medication-related burden quality of life (MRB-QoL) tool: Cross-cultural adaptation and content validation.

Al-Ebrahim S, Harrison J, Chen T, Alzubaidi H, Mohammed M Explor Res Clin Soc Pharm. 2024; 16:100523.

PMID: 39498226 PMC: 11532770. DOI: 10.1016/j.rcsop.2024.100523.

Assessment of Pharmacists' Willingness to Conduct Medication Use Reviews in Poland.

Merks P, Religioni U, Waszyk-Nowaczyk M, Kazmierczak J, Bialoszewski A, Blicharska E Int J Environ Res Public Health. 2022; 19(3).

PMID: 35162889 PMC: 8835186. DOI: 10.3390/ijerph19031867.

References

Hugtenburg J, Timmers L, Elders P, Vervloet M, van Dijk L . Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Prefer Adherence. 2013; 7:675-82. PMC: 3711878. DOI: 10.2147/PPA.S29549. View

Latif A . Community pharmacy Medicines Use Review: current challenges. Integr Pharm Res Pract. 2018; 7:83-92. PMC: 6042500. DOI: 10.2147/IPRP.S148765. View

Kempen T, van de Steeg-van Gompel C, Hoogland P, Liu Y, Bouvy M . Large scale implementation of clinical medication reviews in Dutch community pharmacies: drug-related problems and interventions. Int J Clin Pharm. 2014; 36(3):630-5. DOI: 10.1007/s11096-014-9947-4. View

McCambridge J, Witton J, Elbourne D . Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2013; 67(3):267-77. PMC: 3969247. DOI: 10.1016/j.jclinepi.2013.08.015. View

Katusiime B, Corlett S, Krska J . Development and validation of a revised instrument to measure burden of long-term medicines use: the Living with Medicines Questionnaire version 3. Patient Relat Outcome Meas. 2018; 9:155-168. PMC: 5978458. DOI: 10.2147/PROM.S151143. View

Hatah E, Tordoff J, Duffull S, Cameron C, Braund R . Retrospective examination of selected outcomes of Medicines Use Review (MUR) services in New Zealand. Int J Clin Pharm. 2014; 36(3):503-12. DOI: 10.1007/s11096-014-9913-1. View

Messerli M, Blozik E, Vriends N, Hersberger K . Impact of a community pharmacist-led medication review on medicines use in patients on polypharmacy--a prospective randomised controlled trial. BMC Health Serv Res. 2016; 16:145. PMC: 4842295. DOI: 10.1186/s12913-016-1384-8. View

Griese-Mammen N, Hersberger K, Messerli M, Leikola S, Horvat N, van Mil J . PCNE definition of medication review: reaching agreement. Int J Clin Pharm. 2018; 40(5):1199-1208. DOI: 10.1007/s11096-018-0696-7. View

Moher D, Hopewell S, Schulz K, Montori V, Gotzsche P, Devereaux P . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2011; 10(1):28-55. DOI: 10.1016/j.ijsu.2011.10.001. View

10.

Bress A, Bellows B, King J, Hess R, Beddhu S, Zhang Z . Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2017; 377(8):745-755. PMC: 5708850. DOI: 10.1056/NEJMsa1616035. View

11.

. 46th ESCP symposium on clinical pharmacy "Science meets practice: towards evidence-based clinical pharmacy services", Heidelberg, Germany, October 9th-11th, 2017. Int J Clin Pharm. 2017; 40(1):203-317. DOI: 10.1007/s11096-017-0565-9. View

12.

Vinks T, Egberts T, de Lange T, De Koning F . Pharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trial. Drugs Aging. 2009; 26(2):123-33. DOI: 10.2165/0002512-200926020-00004. View

13.

Vrijens B, Belmans A, Matthys K, de Klerk E, Lesaffre E . Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf. 2005; 15(2):115-21. DOI: 10.1002/pds.1198. View

14.

Osterberg L, Blaschke T . Adherence to medication. N Engl J Med. 2005; 353(5):487-97. DOI: 10.1056/NEJMra050100. View

15.

Cline C, Israelsson B, Willenheimer R, Erhardt L . Non-compliance and knowledge of prescribed medication in elderly patients with heart failure. Eur J Heart Fail. 2000; 1(2):145-9. DOI: 10.1016/s1388-9842(99)00014-8. View

16.

Engels J, Diehr P . Imputation of missing longitudinal data: a comparison of methods. J Clin Epidemiol. 2003; 56(10):968-76. DOI: 10.1016/s0895-4356(03)00170-7. View

17.

Lamina C, Sturm G, Kollerits B, Kronenberg F . Visualizing interaction effects: a proposal for presentation and interpretation. J Clin Epidemiol. 2012; 65(8):855-62. DOI: 10.1016/j.jclinepi.2012.02.013. View

18.

Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon J . Effectiveness of pharmacist intervention for asthma control improvement. Eur Respir J. 2007; 31(4):790-9. DOI: 10.1183/09031936.00112007. View

19.

Vrijens B, de Geest S, Hughes D, Przemyslaw K, Demonceau J, Ruppar T . A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5):691-705. PMC: 3403197. DOI: 10.1111/j.1365-2125.2012.04167.x. View

20.

Messerli M, Vriends N, Hersberger K . Humanistic outcomes and patient acceptance of the pharmacist-led medication review "Polymedication Check" in primary care in Switzerland: a prospective randomized controlled trial. Patient Prefer Adherence. 2018; 12:1071-1078. PMC: 6016257. DOI: 10.2147/PPA.S160789. View